HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Somatostatin receptor-targeted organometallic iridium(iii) complexes as novel theranostic agents.

Abstract
A novel somatostatin receptor-targeted anticancer agent based on the conjugation of a highly cytotoxic and luminescent cyclometalated iridium(iii) complex to tumor-targeting vectors based on octreotide peptide has been described, and its potential for targeted theranostic applications has been demonstrated.
AuthorsVojtech Novohradsky, Ana Zamora, Albert Gandioso, Viktor Brabec, José Ruiz, Vicente Marchán
JournalChemical communications (Cambridge, England) (Chem Commun (Camb)) Vol. 53 Issue 40 Pg. 5523-5526 (May 17 2017) ISSN: 1364-548X [Electronic] England
PMID28466888 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: